A
Andreas Engert
Researcher at Cochrane Collaboration
Publications - 47
Citations - 1669
Andreas Engert is an academic researcher from Cochrane Collaboration. The author has contributed to research in topics: Hazard ratio & Cancer. The author has an hindex of 13, co-authored 47 publications receiving 1578 citations. Previous affiliations of Andreas Engert include University of Hamburg & University of Cologne.
Papers
More filters
Journal ArticleDOI
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
Julia Bohlius,Kurt Schmidlin,Corinne Brillant,Guido Schwarzer,Sven Trelle,Jerome Seidenfeld,Marcel Zwahlen,Mike Clarke,Mike Clarke,Olaf Weingart,Sabine Kluge,Margaret Piper,Dirk Rades,David P. Steensma,Benjamin Djulbegovic,Martin F. Fey,Isabelle Ray-Coquard,Mitchell Machtay,Volker Moebus,Gillian Thomas,Michael Untch,Martin Schumacher,Matthias Egger,Andreas Engert +23 more
TL;DR: Treatment with erythropoiesis-stimulating agents in patients with cancer increased mortality during active study periods and worsened overall survival, and the increased risk of death associated with treatment with these drugs should be balanced against their benefits.
Journal ArticleDOI
Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.
Andreas Draube,Nela Klein-Gonzalez,Stefanie Mattheus,Corinne Brillant,Martin Hellmich,Andreas Engert,Michael von Bergwelt-Baildon +6 more
TL;DR: A statistically significant effect of DC-mediated cellular immune response and of DC dose on CBR could be demonstrated and is a 'proof of principle' for the immunological development of Washington DC-based vaccines.
Journal ArticleDOI
Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis
Nicole Skoetz,Sven Trelle,Michaela Rancea,Heinz Haverkamp,Volker Diehl,Andreas Engert,Peter Borchmann +6 more
TL;DR: Six cycles of BEACOPPescalated significantly improves overall survival compared with ABVD and other regimens, and thus this treatment strategy is recommended as standard of care for patients with access to the appropriate supportive care.
Journal ArticleDOI
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.
Julia Bohlius,Kurt Schmidlin,Corinne Brillant,Guido Schwarzer,Sven Trelle,Jerome Seidenfeld,Marcel Zwahlen,Mike Clarke,Olaf Weingart,Sabine Kluge,Margaret Piper,Maryann Napoli,Dirk Rades,David P. Steensma,Benjamin Djulbegovic,Martin F. Fey,Isabelle Ray-Coquard,Volker Moebus,Gillian Thomas,Michael Untch,Martin Schumacher,Matthias Egger,Andreas Engert +22 more
TL;DR: ESA treatment in cancer patients increased on study mortality and worsened overall survival, and for patients undergoing chemotherapy the increase was less pronounced, but an adverse effect could not be excluded.
Journal ArticleDOI
Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.
Holger Schulz,Julia Bohlius,Nicole Skoetz,Sven Trelle,Thilo Kober,Marcel Reiser,Martin Dreyling,Michael Herold,Guido Schwarzer,Michael Hallek,Andreas Engert +10 more
TL;DR: Improved OS for patients with indolent lymphoma, particularly in the subgroups of follicular and in mantle cell lymphoma when treated with R-chemo compared to chemotherapy alone is demonstrated.